New kid on the block: Roger Perlmutter's biotech signs on as anchor tenant to new Bay Area campus
Having left behind a stellar legacy in Merck’s headquarters in Kenilworth, NJ, Roger Perlmutter’s next chapter of drug R&D will be written in the San Francisco Bay Area.
Eikon Therapeutics, the ambitious biotech startup helmed by Perlmutter, has signed a long-term lease to set up its new corporate headquarters in a new life sciences campus being developed by Alexandria Real Estate Equities in Millbrae, CA. As the anchor tenant, Eikon will command about 285,000 square feet — enough to accommodate up to 750 employees.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,300+ biopharma pros reading Endpoints daily — and it's free.